CN Patent

CN108112254B — 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法

Assigned to Cytomx Therapeutics Inc · Expires 2022-01-28 · 4y expired

What this patent protects

本发明一般地涉及结合程序性死亡配体1(PDL1)的抗体、特异性地结合PDL1的可活化抗体和在多种治疗、诊断和预防适应症中制备和使用这些抗‑PDL1抗体和抗‑PDL1可活化抗体的方法。

USPTO Abstract

本发明一般地涉及结合程序性死亡配体1(PDL1)的抗体、特异性地结合PDL1的可活化抗体和在多种治疗、诊断和预防适应症中制备和使用这些抗‑PDL1抗体和抗‑PDL1可活化抗体的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108112254B
Jurisdiction
CN
Classification
—
Expires
2022-01-28
Drug substance claim
No
Drug product claim
No
Assignee
Cytomx Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.